Finzati - Logo
IDXX logo

IDEXX Laboratories, Inc.

IDXX • Medical - Diagnostics & Research
$535.38
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$46.13B
Growth
15.7%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 24.6%Positive revenue growth · 9.2%Positive free cash flow · 13.15Consistent free cash flow · 5/5Manageable debt level · 0.67
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 6, 2026, 12:16 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$535.38
Change0.00%
Market Cap$46.13B
52W Range518.55 - 769.98
Beta1.55
Dividend Yield0.00%
Gross Margin61.80%
Oper. Margin31.60%
Profit Margin24.62%
Debt/Eq0.67
Current Ratio1.17
Quick Ratio0.84

Investment DNA

How strong this company looks for long-term investors

77
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
93/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score▼
Stable or improving margins · 24.6%Positive revenue growth · 9.2%Positive free cash flow · 13.15Consistent free cash flow · 5/5Manageable debt level · 0.67Expensive earnings multiple · 51.15

Analyst view

Analyst sentiment and price target

IDXX
Analyst sentiment
Based on 23 analyst votes · 2026-09-05
76/100
Bullish
Bullish
13
Hold
9
Bearish
1
Price Target
2026-08-06
Low
$620.00
Mean
$685.00
Median
$685.00
High
$750.00

Company Overview

IPO: 6/21/1991
Industry: Medical - Diagnostics & Research
P/B i: 33.75
Debt / Equity i: 0.67
Operating Margin: 31.60%
Net Margin: 24.62%
ROE i: -
ROIC: -

Financial Health

Score14 / 20
Debt / Equity: 0.67
Current Ratio: 1.17
Quick Ratio: 0.84
Status: Good

Insider Transactions

Recent executive and insider activity

HOOLEY JOSEPH L
Transaction: 07/30/2026
BUY
Change
+49
Price
$558.80
Filing
08/03/2026
Type
BUY
FENNELL GEORGE
Transaction: 06/01/2026
SELL
Change
-639
Price
Not reported
Filing
06/02/2026
Type
SELL
FENNELL GEORGE
Transaction: 06/01/2026
SELL
Change
-284
Price
$566.79
Filing
06/02/2026
Type
SELL